Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 31Neoplasms 9Neoplasm Metastasis 5Colorectal Neoplasms 3Wilms Tumor 2Skin Neoplasms 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Lymphoma, Non-Hodgkin 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Glioma 2Ependymoma 2Central Nervous System Neoplasms 2Xanthogranuloma, Juvenile 1Urinary Bladder Neoplasms 1Thyroid cancer, follicular 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Skin Diseases 1Pancreatic Neoplasms 1Neoplasms, Unknown Primary 1Multiple Myeloma 1Medulloblastoma 1Lymphoma 1

Interventions

Alpelisib 4berzosertib 3Fulvestrant 3Everolimus 3parsaclisib 2Topotecan 2NVP-BKM120 2Cetuximab 2talazoparib 1sotorasib 1serabelisib 1ruxolitinib 1duvelisib 1dapagliflozin 1cobimetinib 1ceralasertib 1binimetinib 1avelumab 1Vemurafenib 1SF 1126 1Rituximab 1Paclitaxel 1Oxaliplatin 1Leuprolide 1Leucovorin 1Letrozole 1Irinotecan 1Goserelin 1Fluorouracil 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Hereditary Sensory and Autonomic Neuropathies × Vemurafenib × Clear all
NCT01942993 2020-09-30

The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma

Icahn School of Medicine at Mount Sinai

Phase 2 Terminated
3 enrolled 2 charts
Dermatologic

Melanoma, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡